Ioana R. Preston
Experienced in Obstructive Sleep Apnea

Dr. Ioana R. Preston

Intensive Care Medicine | Pulmonary Medicine
Lahey Clinic Inc
41 Mall Rd, 
Burlington, MA 
Accepting New Patients
Experienced in Obstructive Sleep Apnea
Lahey Clinic Inc
41 Mall Rd, 
Burlington, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ioana Preston is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Burlington, Massachusetts. Dr. Preston is rated as an Experienced provider by MediFind in the treatment of Obstructive Sleep Apnea. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Heart Failure with Preserved Ejection Fraction (HFpEF), Cerebral Hypoxia, and Lung Transplant. Dr. Preston is currently accepting new patients.

Her clinical research consists of co-authoring 89 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Pulmonary Medicine
Licenses
Critical Care Medicine in RI
Hospital Affiliations
Winchester Hospital
Lahey Hospital & Medical Center, Burlington
Northeast Hospital Corporation
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

LAHEY CLINIC INC
41 Mall Rd, Burlington, MA 01805

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Active_not_recruiting
Publish Date: June 24, 2025
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by CPET in Subjects With WHO Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
Enrollment Status: Terminated
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004
Enrollment Status: Terminated
Publish Date: February 22, 2022
Intervention Type: Drug
Study Drug: Pemziviptadil
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 5 Less Clinical Trials

89 Total Publications

Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
Journal: The New England journal of medicine
Published: September 30, 2025
Similar Doctors
Elite in Obstructive Sleep Apnea
Dr. Robert J. Thomas
Sleep Medicine | Neurology | Pulmonary Medicine
Elite in Obstructive Sleep Apnea
Dr. Robert J. Thomas
Sleep Medicine | Neurology | Pulmonary Medicine

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

148 Chestnut St, 
Needham, MA 
 (14.4 miles away)
781-983-9088
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Thomas is a Sleep Medicine specialist and a Neurologist in Needham, Massachusetts. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Obstructive Sleep Apnea. His top areas of expertise are Central Sleep Apnea, Obstructive Sleep Apnea, Idiopathic Hypersomnia, and Irregular Sleep-Wake Syndrome. Dr. Thomas is currently accepting new patients.

Distinguished in Obstructive Sleep Apnea
Dr. Michael L. Stanchina
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Distinguished in Obstructive Sleep Apnea
Dr. Michael L. Stanchina
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Affinity Physicians Llc.

455 Toll Gate Rd, 
Warwick, RI 
 (55.6 miles away)
401-737-7010
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Stanchina is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Warwick, Rhode Island. Dr. Stanchina is rated as a Distinguished provider by MediFind in the treatment of Obstructive Sleep Apnea. His top areas of expertise are Obstructive Sleep Apnea, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Pneumonia.

Distinguished in Obstructive Sleep Apnea
Dr. Rohit Budhiraja
Sleep Medicine | Intensive Care Medicine | Pulmonary Medicine
Distinguished in Obstructive Sleep Apnea
Dr. Rohit Budhiraja
Sleep Medicine | Intensive Care Medicine | Pulmonary Medicine

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (11.4 miles away)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rohit Budhiraja is a Sleep Medicine specialist and an Intensive Care Medicine provider in Boston, Massachusetts. Dr. Budhiraja is rated as a Distinguished provider by MediFind in the treatment of Obstructive Sleep Apnea. His top areas of expertise are Obstructive Sleep Apnea, Restless Legs Syndrome, Excessive Daytime Sleepiness, and Insomnia. Dr. Budhiraja is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Preston's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile